Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:15:42 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:CHRS - COHERUS ONCOLOGY INC - https://www.coherus.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CHRS - Q2.52.12·10.000.32.14+0.052.42,444.64,9734,9382.15  2.195  2.022.6158  0.7119:49:00Jan 1215 min RT 2¢

Recent Trades - Last 10 of 4938
Time ETExPriceChangeVolume
19:49:00Q2.150.065
19:35:49Q2.15880.0688355
19:13:08Q2.12170.0317500
19:12:05Q2.12160.0316490
19:10:57Q2.14010.0501300
17:50:11Q2.140.05500
17:50:11Q2.14240.0524500
17:48:34Q2.14030.050310
17:43:15Q2.140.05107
17:39:05Q2.12080.0308100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-12 10:14U:CHRSNews ReleaseThe $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
2026-01-06 09:30U:CHRSNews ReleaseCoherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-06 08:00U:CHRSNews ReleaseSpyGlass Pharma Appoints Jean-Frederic Viret as Chief Financial Officer
2026-01-05 09:30U:CHRSNews ReleaseCoherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
2025-12-08 08:30U:CHRSNews ReleaseCoherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI(TM) plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
2025-11-07 09:00U:CHRSNews ReleaseCoherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
2025-11-06 16:14U:CHRSNews ReleaseCoherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-06 13:55U:CHRSNews ReleaseArvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
2025-10-30 08:30U:CHRSNews ReleaseCoherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
2025-10-23 08:30U:CHRSNews ReleaseCoherus Oncology to Participate in Upcoming Investor Conferences
2025-10-03 09:06U:CHRSNews ReleaseCoherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2025-09-03 08:30U:CHRSNews ReleaseCoherus Oncology to Participate in Upcoming Investor Conferences
2025-08-07 16:41U:CHRSNews ReleaseCoherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-31 16:45U:CHRSNews ReleaseCoherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
2025-05-30 08:00U:CHRSNews ReleaseCoherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
2025-05-27 08:30U:CHRSNews ReleaseCoherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI(TM) (toripalimab-tpzi)
2025-05-12 16:15U:CHRSNews ReleaseCoherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-05 16:01U:CHRSNews ReleaseCoherus to Report First Quarter 2025 Financial Results on May 12, 2025
2025-05-01 17:04U:CHRSNews ReleaseCoherus to Participate in Upcoming Investor Conferences
2025-04-28 10:10U:CHRSNews ReleaseCoherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025